News &amp; Updates

A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.

Oral paclitaxel on par with IV formulation in HER2-negative breast cancer

08 Jul 2026

More complications, readmissions seen in RCC patients with comorbidities

Renal cell carcinoma (RCC) patients with comorbidities are at greater risk for postoperative kidney and urinary complications and readmissions, reports a study, noting the importance of comorbidity management in surgical care in this population.

More complications, readmissions seen in RCC patients with comorbidities

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Engaging in resistance training over midlife and limiting sedentary behaviour have been shown to substantially lower the risk of type 2 diabetes (T2D) in a study.

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

In patients with Janus kinase inhibitor (JAKi)-naïve myelofibrosis, the addition of selinexor to ruxolitinib significantly improves the incidence of spleen volume reduction of ≥35 percent (SVR35) compared with ruxolitinib alone, according to the SENTRY trial presented at ASCO 2026.

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

Triple win for fixed-dose combo in T2D

A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA_1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.

Triple win for fixed-dose combo in T2D

08 Jul 2026

No clear link between prenatal acid suppressant use and IBD in offspring

In vitro exposure to acid-suppressive medications does not appear to be associated with an increased risk of inflammatory bowel disease (IBD) development in offspring, as shown in a nationwide cohort study.

No clear link between prenatal acid suppressant use and IBD in offspring

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026 by

The overall development of vision-threatening diabetic retinopathy (DR) among Asians with diabetes is low, although the incidence of progression to vision-threatening disease for those who already have DR is high, according to local research.

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Comorbidities delay RT in patients with brain tumours

Patients with malignant brain tumours and several comorbidities tend to have delayed radiotherapy (RT), reveals a study.

Comorbidities delay RT in patients with brain tumours

Efgartigimod improves platelet response in primary ITP

07 Jul 2026 by

The use of efgartigimod in adult patients with primary immune thrombocytopenia (ITP) results in higher platelet response with no increase in serious adverse events (AEs), reports a meta-analysis of phase III randomized controlled trials (RCTs).

Efgartigimod improves platelet response in primary ITP